Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization

Sangheun Lee, Jung Hyun Kang, doyoung kim, SangHoon Ahn, Junyong Park, Beom Kyung Kim, Seungup Kim, KwangHyub Han

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: There is no approved therapy for patients with failed transarterial chemoembolization (TACE) and progression of hepatocellular carcinoma. We aimed to investigate the efficacy and prognostic factors in patients with TACE failure who received sorafenib rescue therapy. Methods: We investigated 54 patients who met the criteria of TACE failure as defined by the international guidelines of Europe and Japan. Sorafenib was used as a rescue therapy. Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier methods, and multivariate analysis was performed to find prognostic factors. Results: The patients were followed for a median 5.5 months, and the median duration of sorafenib administration was 3.3 months. The presence of main (or lobar) portal vein invasion (PVI) (3.7 versus 8.4 months, p = 0.004), dose reduction of sorafenib (4.0 versus 8.8 months, p = 0.002) and Child-Pugh class B (5.3 versus 8.9 months, p = 0.004) were associated with shorter OS compared to the presence of segmental PVI (or absence of macroscopic vascular invasion, MVI), full dosage of sorafenib and Child-Pugh class A, respectively. The presence of main (or lobar) PVI was associated with poorer PFS compared to the presence of segmental PVI (or absence of MVI) (2.1 versus 3.8 months p = 0.010). Conclusions: Sorafenib is a potential rescue therapy in patients with TACE failure. However, the clinical benefits need to be further evaluated for patients with main (or lobar) PVI or those treated with reduced doses of sorafenib.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalHepatology International
Volume11
Issue number3
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Hepatocellular Carcinoma
Portal Vein
Therapeutics
Disease-Free Survival
Blood Vessels
Survival
Kaplan-Meier Estimate
sorafenib
Japan
Multivariate Analysis
Guidelines

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

@article{b2f579e19b2d451d9364a9dd7f23a1b1,
title = "Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization",
abstract = "Background: There is no approved therapy for patients with failed transarterial chemoembolization (TACE) and progression of hepatocellular carcinoma. We aimed to investigate the efficacy and prognostic factors in patients with TACE failure who received sorafenib rescue therapy. Methods: We investigated 54 patients who met the criteria of TACE failure as defined by the international guidelines of Europe and Japan. Sorafenib was used as a rescue therapy. Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier methods, and multivariate analysis was performed to find prognostic factors. Results: The patients were followed for a median 5.5 months, and the median duration of sorafenib administration was 3.3 months. The presence of main (or lobar) portal vein invasion (PVI) (3.7 versus 8.4 months, p = 0.004), dose reduction of sorafenib (4.0 versus 8.8 months, p = 0.002) and Child-Pugh class B (5.3 versus 8.9 months, p = 0.004) were associated with shorter OS compared to the presence of segmental PVI (or absence of macroscopic vascular invasion, MVI), full dosage of sorafenib and Child-Pugh class A, respectively. The presence of main (or lobar) PVI was associated with poorer PFS compared to the presence of segmental PVI (or absence of MVI) (2.1 versus 3.8 months p = 0.010). Conclusions: Sorafenib is a potential rescue therapy in patients with TACE failure. However, the clinical benefits need to be further evaluated for patients with main (or lobar) PVI or those treated with reduced doses of sorafenib.",
author = "Sangheun Lee and Kang, {Jung Hyun} and doyoung kim and SangHoon Ahn and Junyong Park and Kim, {Beom Kyung} and Seungup Kim and KwangHyub Han",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s12072-017-9792-3",
language = "English",
volume = "11",
pages = "292--299",
journal = "Hepatology International",
issn = "1936-0533",
publisher = "Springer New York",
number = "3",

}

Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. / Lee, Sangheun; Kang, Jung Hyun; kim, doyoung; Ahn, SangHoon; Park, Junyong; Kim, Beom Kyung; Kim, Seungup; Han, KwangHyub.

In: Hepatology International, Vol. 11, No. 3, 01.05.2017, p. 292-299.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization

AU - Lee, Sangheun

AU - Kang, Jung Hyun

AU - kim, doyoung

AU - Ahn, SangHoon

AU - Park, Junyong

AU - Kim, Beom Kyung

AU - Kim, Seungup

AU - Han, KwangHyub

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: There is no approved therapy for patients with failed transarterial chemoembolization (TACE) and progression of hepatocellular carcinoma. We aimed to investigate the efficacy and prognostic factors in patients with TACE failure who received sorafenib rescue therapy. Methods: We investigated 54 patients who met the criteria of TACE failure as defined by the international guidelines of Europe and Japan. Sorafenib was used as a rescue therapy. Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier methods, and multivariate analysis was performed to find prognostic factors. Results: The patients were followed for a median 5.5 months, and the median duration of sorafenib administration was 3.3 months. The presence of main (or lobar) portal vein invasion (PVI) (3.7 versus 8.4 months, p = 0.004), dose reduction of sorafenib (4.0 versus 8.8 months, p = 0.002) and Child-Pugh class B (5.3 versus 8.9 months, p = 0.004) were associated with shorter OS compared to the presence of segmental PVI (or absence of macroscopic vascular invasion, MVI), full dosage of sorafenib and Child-Pugh class A, respectively. The presence of main (or lobar) PVI was associated with poorer PFS compared to the presence of segmental PVI (or absence of MVI) (2.1 versus 3.8 months p = 0.010). Conclusions: Sorafenib is a potential rescue therapy in patients with TACE failure. However, the clinical benefits need to be further evaluated for patients with main (or lobar) PVI or those treated with reduced doses of sorafenib.

AB - Background: There is no approved therapy for patients with failed transarterial chemoembolization (TACE) and progression of hepatocellular carcinoma. We aimed to investigate the efficacy and prognostic factors in patients with TACE failure who received sorafenib rescue therapy. Methods: We investigated 54 patients who met the criteria of TACE failure as defined by the international guidelines of Europe and Japan. Sorafenib was used as a rescue therapy. Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier methods, and multivariate analysis was performed to find prognostic factors. Results: The patients were followed for a median 5.5 months, and the median duration of sorafenib administration was 3.3 months. The presence of main (or lobar) portal vein invasion (PVI) (3.7 versus 8.4 months, p = 0.004), dose reduction of sorafenib (4.0 versus 8.8 months, p = 0.002) and Child-Pugh class B (5.3 versus 8.9 months, p = 0.004) were associated with shorter OS compared to the presence of segmental PVI (or absence of macroscopic vascular invasion, MVI), full dosage of sorafenib and Child-Pugh class A, respectively. The presence of main (or lobar) PVI was associated with poorer PFS compared to the presence of segmental PVI (or absence of MVI) (2.1 versus 3.8 months p = 0.010). Conclusions: Sorafenib is a potential rescue therapy in patients with TACE failure. However, the clinical benefits need to be further evaluated for patients with main (or lobar) PVI or those treated with reduced doses of sorafenib.

UR - http://www.scopus.com/inward/record.url?scp=85028241847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028241847&partnerID=8YFLogxK

U2 - 10.1007/s12072-017-9792-3

DO - 10.1007/s12072-017-9792-3

M3 - Article

C2 - 28324324

AN - SCOPUS:85028241847

VL - 11

SP - 292

EP - 299

JO - Hepatology International

JF - Hepatology International

SN - 1936-0533

IS - 3

ER -